Michelle Melisko

Clinical Professor of Medicine

University of California, San Francisco
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.

Year:

2024

Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.

Year:

2024

Collaborators (21)

Nola Hylton

Professor

University of California, San Francisco

UNITED STATES
View details

Lajos Pusztai

Yale University

UNITED STATES
View details

Amy Clark

Assistant Professor of Medicine

University of Pennsylvania

UNITED STATES
View details

Amy Jo Chien

Professor of Clinical Medicine Medical Director, Breast Oncology

University of California, San Francisco

UNITED STATES
View details

Sarah Blair

Professor

UC San Diego Health System

UNITED STATES
View details

Angela DeMichele

University of Pennsylvania

UNITED STATES
View details

W. Fraser Symmans

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kathy Albain

Professor of Medicine

Loyola University Chicago Stritch School of Medicine

UNITED STATES
View details

Julie E. Lang

University of Southern California

UNITED STATES
View details

Rita Nanda

Associate Professor of Medicine; Director Breast Oncology

University of Chicago

UNITED STATES
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Yunn-Yi Chen

Professor

UCSF Medical Center

UNITED STATES
View details

Erica M. Stringer-Reasor

Associate Professor

The University of Alabama

UNITED STATES
View details

Gillian Hirst

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Rosa Isela Gallagher

Senior Research Scientist

George Mason University

UNITED STATES
View details

Douglas Yee

Professor

University of Minnesota

UNITED STATES
View details

Laura Esserman

University of California

UNITED STATES
View details

Claudine Isaacs

Professor of Medicine

Georgetown University

UNITED STATES
View details

Laura J. van 't Veer

University of California, San Francisco

UNITED STATES
View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES
View details

David Potter

Associate Professor

University of Minnesota

UNITED STATES
View details